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Nanotechnology is a nanoscale (1 to 100 
nanometers) research and technology used for 
its use in various fields of science, such as 
pharmacy, medical science, materials science 
and engineering. (1) Today, research in 
"nanotechnology" is moving around the world 
to upgrade modern medical methodologies and 
to develop novel techniques for manufacturing 
high-precision and durable products in the labs 
all over the world. In the pharmaceutical 
sector, genuinely innovative products, 
materials and applications are arriving. 
'Nanotech' products currently on the market are 
mainly progressively improved materials 
(using advanced nanotechnology) where some 
type of nano-enabled material (such as carbon 
nanotubes, nanocomposite structures or 
nanoparticles of a specific substance) or 
nanotechnology processes (such as 
nanopatterning or medical imaging quantum 
dots) are used in the production process. (2) 
At an American Physical Society conference at 
the California Institute of Technology ( 
CalTech) on December 29, 1959, long before 
the word nanotechnology was used, the 
evidence and knowledge behind nanoscience 
and nanotechnology began with a talk entitled 
"There's Plenty of Space at the Bottom" by 
physicist Richard Feynman. In his lecture, 
Feynman outlined a mechanism in which 
individual atoms and molecules could be 
regulated and controlled by scientists. 
Professor Norio Taniguchi invented the term 
nanotechnology more than a decade back, in 
his explorations in ultra-precision machining. 
It was not until 1981 that modern 
nanotechnology began with the invention of 
the scanning tunnelling microscope that could 
'see' individual atoms. (3) 
The rise of nanoscience and 
nanotechnology, which develops and utilises 
nanometer-scale materials and instruments, has 
had a significant effect on a variety of 
industries, especially the pharmaceutical 
industry. (4) Much as recombinant 
technologies and biotechnology have altered 
the pharmaceutical business environment, 
nanotechnology is expected to push today's 
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cross-road pharmaceutical sector to new 
heights. (5) 
However, nanotechnology has broader 
applications, unlike the biotechnology industry 
that primarily influenced the pharmaceutical 
industry, and therefore the nanotechnology 
instruments and materials developed for other 
industries also have potential opportunities in 
the pharmaceutical industry. (6) Furthermore, 
there is a common notion that the tools of 
nanotechnology are exotic, too futuristic, 
disruptive and not suitable for rapid product 
commercialization. (7) As nanotechnology 
tools are shown to add value to existing 
products for existing markets as well as open 
up opportunities in new markets, this notion is 
far from true. 
This is not only true for the pharmaceutical 
industry, but for other fields as well. What is 
obviously missing, nevertheless, is a blueprint 
for sorting out the multitude of current 
nanotechnology resources and creatively 
correlating them with future prospects in 
various pharmaceutical R&D segments. (8) 
Furthermore, as a modern model of treatment 
that combines therapeutics with diagnostics, 
there will be a paradigm change in the 
pharmaceutical industry towards personalised 
medicine. Therefore, it is important to 
establish a more scientific approach for the 
strategic application in the pharmaceutical 
industry of nanotechnological instruments. (9) 
With the worldwide burden of the COVID-19 
pandemic accelerating, experts are actively 
looking for a suitable antidote or therapy to 
tackle the worldwide public health emergency. 
Main research breakthroughs and 
advancements that are currently ongoing are as 
follows: 
 Business study of COVID-19 nano-based 
diagnostic devices, including gold 
nanoparticles, iron oxide nanoparticles, 
graphene, quantum dots, mercury quantum 
dots and carbon nanotubes containing 
nanosensors. Updated consumer sales to 
pandemic results. In-depth business 
profiles. Abbott Laboratories, Cardea, 
Ferrotec (USA) Corporation, E25Bio, 
Grolltex, Inc., Luminex Corporation, etc. 
are the businesses profiled. 
 Business study of antiviral and 
antimicrobial nano-coatings for surfaces 
like cloth (masks, caps, doctor's suits, 
curtains, bed sheets), metal (lifts, door 
handles, nobs, tracks, public transport), 
wood (furniture, floors and partition 
panels), concrete (hospitals, clinics and 
insulation rooms) and plastics (switches, 
kitchens and appliances). 
 Adjusted consumer revenues with 
pandemic results. In-depth market profiles. 
Advanced Materials-JTJ s.r.o., Bio-Fence, 
Bio-Gate AG, Covalon Technologies Ltd., 
EnvisionSQ, GrapheneCA, Integricote, 
Nano Came Co. are among the companies 
profiled. Ltd., Fabrics for NanoTouch, 
LLC, NitroPep and several more. 
 Business study of airborne virus filtration, 
including Nano-TiO2 photocatalytic 
philtres, philtres of nanofiber, nanosilver, 
nanocellulose, filtration of graphene and 
carbon nanotube. Updated consumer sales 
to pandemic results. In-depth market 
profiles. G6 Fabrics, Daicel FineChem 
Ltd., NANOVIA s.r.o., Toray Industries, 
Inc., Tortech Nano Fibers, etc. are the 
businesses profiled. 
 Nano-based facemask industry research 
and other PPE goods. Updated consumer 
sales to pandemic results. In-depth market 
profiles. Profiled firms include 
planarTECH LLC, RESPILON Group, s. r. 
O., SITA, Sonovia Ltd. and so on. 
 The ongoing development of nanotherapies 
and drug delivery vehicles and clinical 
trials of COVID-19 vaccines. Updated 
consumer sales to pandemic results. In-
depth market profiles. Profiled companies 
include Arcturus Therapeutics, Inc., 
BlueWillow Biologics, Arbutus 
Biopharma, Elastrin Therapeutics Inc., 
EnGeneIC Ltd., etc. (10) 
2. Pharmaceutical Nano Systems  
In the pharmaceutical sector, different types 
of nano systems are prepared and used, some 
of which are as follows: 
Polymeric Nanoparticles (PNPs) 
They have a size range of 10-1000 nm and are 
biocompatible and biodegradable to provide 
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complete protection for drugs. PNPs are 
derived from synthetic polymers such as poly-
caprolactone, polyacrylamide and polyacrylate, 
or from natural polymers such as albumin, 
DNA and chitosan gelatin. PNPs can be 
categorised as biodegradable on the basis of in 
vivo actions, i.e. poly(L-lactide) (PLA), 
polyglycolide (PGA), and non-biodegradable, 
e.g. polyurethane. In order to minimise 
immunological interactions ( e.g., opsonization 
or introduction of PNPs to CD8 T-
lymphocytes), as well as intermolecular 
interactions between surface chemical groups 
of PNPs (e.g., van d d-lymphocytes), PNPs are 
usually treated with nonionic surfactants. (11) 
  
 
Figure 1. Polymeric nanoparticles with hydrophobic core and conjugated drug. 
As carriers for regulated and continuous 
drug delivery, polymeric nanoparticles are 
used. Drugs may be immobilised during a 
polymerization reaction on the surface of PNPs 
(as seen in fig.1) or can be encapsulated after a 
polymerization process on the PNP structure. 
In addition, drugs in the target tissue may be 
emitted by desorption, diffusion, or 
nanoparticle erosion. Chemically engineered 
nanoparticle production that envelops flu 
viruses in a 'scaffold' that prevents them from 
infecting host cells. Further preclinical 
research must now be performed to examine if 
the nanoparticle induces immune responses in 
mammals and whether regular administration 
results in resistance until it can be tested in 
humans. 
Dendrimers 
Dendrimers are formed by controlled 
polymerization and have a size of < 10 nm. 
These are strongly branched polymeric mono-
disperse structures of well-defined size and 
composition (as seen in Fig.2). One of the 
most common structures observed in all 
biological systems is dendritic architecture. 
Glycogen, amylopectin and proteoglycans are 
some of the examples of nanometric molecules 
containing dendritic structure. (12) 
 
Figure 2. Dendrimer with highly branched polymeric system. 
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Unlike the linear polymer, the following 
elements can be identified in the dendrimer 
structure: the heart, the dendron, and the 
surface active groups. Dendrons are bound to 
the centre of a single atom or molecule (only if 
it has at least two similar functional groups). 
The dendrons (dendrimer arms) are core-
related monomer molecules that form layers 
and create successive generations (their 
development is limited spatially). Surface 
functional classes decide the biocompatibility 
and physicochemical properties of dendrimers. 
The useability of dendrimers in medical 
applications is defined by the choice of a 
centre, type of monomer and surface functional 
groups. 
Especially important for biomedical purposes 
is the cytotoxicity and polyvalence of 
dendrimers. (13) The cytotoxicity of 
dendrimers relies on the central material and is 
greatly affected by the surface structure of the 
dendrimers. Changing the surface amine 
groups into hydroxyl ones, for example, can 
contribute to lower levels of cytotoxicity. The 
word polyvalence determines the number of 
active groups on the surface of the dendrimers. 
The presence of many functional groups on the 
surface allows for sumultaneous contact with a 
range of receptors, thus increasing biological 
activity. Dendrimers are used to monitor the 
release of drugs and distribute drugs to 
macrophages and the liver in a controlled way. 
Metallic nanoparticles 
Metallic nanoparticles have a size of < 100 
nm and are gold and silver colloids. They are 
very small in bulk, resulting in more surface 
area, and are preferably characterised by a 
substance with more bioavailability and 
stability. These are used for delivery of drugs 
and genes and are used in critical diagnostic 
assays, thermal ablation and enhancement of 
radiotherapy. (14) 
 
Figure 3. Gold nanoparticle with various applications. 
For possible uses (as seen in Fig.3), gold 
nanoparticles (Au NPs) have been intensively 
studied in medical imaging (early 
identification and diagnosis) and cancer 
management (including tumour therapy) and 
drug delivery processes. Gold NPs consist of a 
nucleus of a gold atom surrounded by negative 
surface reactive groups that can be 
conveniently functionalized by adding a 
monolayer of surface moieties (active targeting 
links). Although they can be constructed using 
various chemical and physical pathways, Au 
NPs are usually prepared using the method of 
colloidal synthesis (using a metal precursor, a 
reductant, and a stabiliser) for biomedical 
applications. 
Due to the presence of a negative charge on 
Au NPs, a wide range of different 
biomolecules, including drug molecules, or 
large biomolecules such as antibiotics, 
proteins, genes (DNA and RNA), and a variety 
of targeting ligands can be easily (bio) 
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functionalized (via ionic or covalent bonding 
or physical absorption), while recent research 
has shown their non-toxicity for some human 
beings Due to the existence of the surface 
plasmon resonance ( SPR) bands, Au NPs are 
especially attractive, which allow them to 
convert light to heat and spread the heat 
produced to destroy the cancer cells. (15) 
Silver nanoparticles (Ag NPs) can, with 
their antibacterial and antiviral properties, be 
used to deliver drugs. They can be mixed with 
cationic polymers that contribute to a 
nanomaterial that is bacteriostatic. As an 
environmentally safe material, silver 
nanoparticles can be efficiently used on 
microorganisms and viruses by adding them to 
medical instruments that suppress COVID 
infections in patients and medical teams. 
Nanobots 
Advanced sub-micron-sized nanobots or 
nanomotors are self-driven, biodegradable 
nanodevices made of bio-nano components 
that carry cargo to the target sites. Compared 
to traditional approaches, this active motor-
based drug delivery strategy offers efficient 
and enhanced drug delivery. Gold nanoparticle 
loaded artificial micromotors based on PEDOT 
/ zinc are tested via oral administration in 
mouse models. With high cargo-loading 
capacities, they displayed excellent acid-
driven, self-propulsive properties. (16) 
Nanoghost 
One of the new technologies developed for 
smart drug / gene delivery is the Nanoghost 
system. Nanoghosts are a type of nanovesicles 
extracted from whole biological cells such as 
mesenchymal stem cells (MSCs) that are 
devoid of cytoplasm and organelles from 
naturally functionalized mammalian cell 
surface membranes. These naturally derived 
carriers solve problems with drug activation, 
prevent tumor-specific immune responses, 
provide greater stability of nanoparticles, and 
boost drug release profiles. (17) 
Nanoclews 
Nanoclew, or nanococoon, is a 
biocompatible drug delivery device based on 
DNA. Single stranded DNA renders complete 
nanococoons in this method (as seen in Fig.4). 
It assembles itself by rolling-circle 
amplification to look like a yarn or cocoon or a 
clew-like structure. 
 
Figure 4. Nanoclew with a cocoon like structure. 
Nanoneedles 
In order to achieve high effectiveness and 
minimised side effects, direct supply of 
therapeutic molecules to cell cytoplasm is 
highly desirable in drug delivery. Yet 
biological membranes act as effective barriers 
to drug entry into the cell. To solve these 
problems, Nanoneedles may help. 
Nanoneedles are very small (as seen in Fig.5) 
and allow biological membranes to be briefly 
perforated. Hence, these needles can deliver 
the drugs without disturbing the body's 
biological functions. (18) 
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Figure 5. Nanoneedle like structure of size of very small range. 
Nanobubbles 
Sometimes stabilised by polymeric / lipid 
membranes, nanobubbles are gas-filled 
spherical nano-sized structures. These 
nanocarriers are used as more effective 
imaging and drug delivery agents in various 
clinical therapies in combination with thermal, 
ultrasound, acoustic or magnetic sensitivities. 
They are more stable and showed longer 
residence time in systemic circulation. (19) 
Exosomes 
Exosomes are small biological nanoparticles 
that transfer information between cells and 
provide tremendous potential for disease 
detection and treatment. Exosomes are the 
most promising nano-vehicles of the next 
decade for selective delivery of medicines and 
genomes. There are nano-sized vesicles (40-
200 nm in diameter) originating from patients 
whose own healthy cells are extraordinarily 
capable of communicating with cell 
membranes. They have a peculiar property of 
'cell-based tropism' (targeting specific cells by 
revealing receptors in the membranes) against 
the originating cells, which can be used to 
carry cargo consisting of medicines, proteins 
and microRNAs as a delivery technique. (20) 
Magnetic nanoparticles 
Magnetic nanoparticles possess a wide 
range of properties, making them highly 
promising drug delivery carriers. In specific, 
the following are: simple handling with the aid 
of an external magnetic field, the probability of 
using passive and active drug delivery 
methods, sensing ability (MNPs used in MRI) 
and increased target tissue penetration 
resulting in successful therapy at acceptable 
therapeutic doses. In certain cases, however, 
where magnetic nanocarriers have been used, 
problems have resulted in meeting these 
targets. (21) 
Inappropriate characteristics of magnetic 
nanoparticles or an insufficient magnet device 
are most likely associated with this. For 
example, magnetic nanoparticles (fig.6) appear 
to accumulate into larger clusters, sacrificing 
the basic properties associated with their 
limited size and making them impossible to 
control physically. In contrast, the magnetic 
force will not be sufficiently effective to 
overpower the blood flow force and only 
absorb magnetic drugs at the target site. 
Therefore, the design of magnetic drug 
delivery systems needs several considerations 
to be taken into account, such as magnetic 
properties and particle size, magnetic field 
strength, drug loading ability, target tissue 
accessibility position, or rate of blood flow. 
Liposomes 
Liposomes are phospholipid vesicles with a 
50-100 nm size range with good 
biocompatibility and trapping efficiency 
characteristics. They are spherical vesicles 
made up of phospholipids and steroids (e.g. 
cholesterol), bilayers (fig.7), or other 
surfactants that naturally develop as such lipids 
are distributed in an aqueous atmosphere 
where liposomes, e.g. sonic, may be prepared. 
In order to increase the solubility of drugs and 
enhance their pharmacokinetic properties, 
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liposomes have been documented, such as the 
therapeutic index of chemotherapy agents, 
accelerated metabolism, decreased adverse 
side effects and improved efficacy of in vitro 
and in vivo anti-cancer drugs. (22) 
 
Figure 6. Magnetic nanoparticles with ferrous ferric oxide inside. 
 
 
Figure 7. Liposome structure with lipid bilayer entrapping water soluble drug. 
For passive and active transmission of 
mRNA, proteins and peptides, liposomes are 
often used. Modified liposomes are those lipid 
structures that are a fascinating sort. It is 
possible to use multifunctional liposomes 
containing particular proteins, antigens, or 
other biological substances to produce drugs 
that act selectively on a specific tissue. It is a 
successful path to guided clinical delivery. 
Nanoparticles based on solid lipids 
The types of carrier structures based on 
solid lipid matrix, i.e. solid lipids at body 
temperature, are SLN (solid lipid 
nanoparticles), NLC (nanostructured lipid 
carriers) and LDC (lipid drug conjugates). 
They were utilised for transmission to the 
dermal, peroral, parenteral, ocular, plumonary, 
and rectal. SLN are stable lipid fragments, e.g. 
strongly distilled triglycerides, complex 
mixtures of glycerides or waxes stabilised by 
different surfactants (as seen in fig.8). Good 
physical durability, safety of inserted drugs 
from deterioration, controlled drug release, and 
good tolerability are the key characteristics of 
SLN.  
In addition, some drawbacks have been 
observed, such as lower loading potential 
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(limited by the lipid solubility of the drug and 
the lipid matrix structure and polymorphic 
state), drug expulsion following crystallisation, 




Figure 8. Solid lipid nanoparticles with surfactant and phospholipid. 
NLC and LDC are lipid-based nanoparticle 
modifications that have been developed to 
overcome conventional SLN limitations. NLC 
is formed by combining solid lipids with liquid 
lipids, which leads to an improved payload of a 
special nanostructure and avoids drug 
expulsion. Three forms of NLC have been 
introduced: imperfect NLC type (general 
imperfections in the nanostructure matrix form 
free spaces for guest molecules 
accommodation), multiple NLC type (drugs 
are solved in oils and safe from solid lipid 
degradation) and amorphous NLC type 
(crystallisation that induces drug expulsion is 
avoided). 
Silica materials 
In controlled drug delivery systems, silica 
materials used are known as xerogels and 
mesoporous silica nanoparticles (MSNs), e.g. 
MCM-41 (Mobile Structure of Matter) and 
SBA-15 (Mesoporous Silica Substance of 
Santa Barbara University). As carrier 
structures, they show many benefits, including 
biocompatibility, a highly porous structure and 
ease of functionalization. Silica materials are 
the carriers (as seen in fig. 9) of inorganic 
nanoparticles that are most commonly picked 
for biological purposes. 
 
Figure 9. Mesoporous silica nanoparticles (MSN) in different stages. 
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With high porosity and immense surface area, 
Silica xerogels have an amorphous 
composition. A porous structure is dependent 
on synthesis parameters (shape and pore 
dimensions). The sol-gel technique is 
frequently used to form drug-loaded silica 
xerogels. The alteration of the synthesis 
conditions, such as the reagent ratio, 
temperature, catalyst concentration and drying 
strain, causes the properties of xerogels used in 
the regulated release of drugs to be changed. 
Carbon nanomaterials 
Carbon nanocarriers are differentiated into 
nanotubes (CNTs), carbon dots, nanofibers, 
nanodiamonds, and buckminsterfullerence (as 
seen in fig. 10) used in the drug delivery 
system. CNTs are distinguished by the special 
construction of single (SWNCTs, single walled 
carbon nanotubes) or multi (MWCNTs, multi 
walled carbon nanotubes) graphite layers with 
a large surface area and excellent electronic 
and thermal conductivity. By chemical 
modification of its surface, the 
biocompatibility of nanotubes may be 
improved. Such adjustment can be 
implemented by covalent anchoring of 
PAMAM dendrimers, amphiphilic diblock 
copolymers or PEG layers on CNTs surface or 
dispersion within a hyaluronic acid matrix. 
SWCNTs have been used as a help for 
enhancing the properties of other carriers, such 
as polymeric or non-polymeric composites, 
due to their mechanical strength. 
 
 
Figure 10. Carbon nanocarriers in different forms and design. 
In carbon nanocarriers, there are three forms 
of drug immobilisation: drug encapsulation in 
the carbon nanotube, chemical adsorption on 
the surface or in spaces between nanotubes 
(electrostatic, hydrophobic and hydrogen 
bonds), and binding of active agents to 
functionalized nanotubes of carbon (f-CNTs). 
Encapsulation has the advantage over the other 
two types, since during its delivery to the cells; 
the drug is shielded from degradation and 
released only under particular conditions. (24) 
It is possible to electrically or chemically 
regulate drug release from carbon nanotubes. 
The open ends of CNTs have been sealed with 
polypyrrole (PPy) films to avoid the 
unintended release of the compound. 
Hydrogel nanoparticles 
In recent years, due to their unusual 
properties, hydrogel nanoparticles have gained 
significant popularity as one of the most 
promising nanoparticulate drug delivery 
mechanisms. Hydrogels are cross-linked 
hydrophilic polymer networks (as seen in 
fig.11) that can consume and hold more than 
20% of their weight in water while preserving 
the polymer network’s distinct 3D form at the 
same time. External stimuli or physiological 
parameters may influence the swelling 
properties, network structure, permeability or 
mechanical stability of hydrogels. Hydrogels 
for controlled release of therapeutics, stimulus-
responsive release and applications in 
biological implants have been extensively 
studied. (25) 
Theranostics, where it is possible to use a 
nanoparticle to diagnose and cure pathogens 
that have previously been used with influenza 
and tuberculosis. This method may be 
modified to create nanoparticles of a size 
comparable to COVID-19 that, when applied 
with a combination of infrared light treatment, 
can be connected to the virus that disrupts its 
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structure. This will halt the virus' ability to live 
in the body and replicate. 
 
 
Figure 11. Hydrogel structure with cross-linked networks of hydrophilic polymers. 
3. Characterization of nanoparticles 
Size 
Both in vitro and in vivo, the size of a 
nanoparticle can dictate its behaviour, so 
quantitative data on this feature is important. 
Particle sizing, assembly, numbering, and 
differentiation can be broken down into three 
groups. Ensemble methods, which involve 
multiple spectroscopies such as light and 
acoustic scattering, allow a single device 
calculation and then apply sufficient 
mathematics to derive population size. (26) 
Surface properties 
The particle surface’s contact with its 
surroundings can determine the interaction of 
the particles with each other and may have a 
significant effect on their in vivo behaviour, 
e.g. clearance. Charge, typically calculated as 
zeta potential, is a primary descriptor and is 
most easily determined using methods such as 
scattering of electroacoustic and 
electrophoretic radiation. 
Particle morphology 
Scanning electron microscopy, either in 
transmitting or scanning mode, is the main 
instrument of the analyst, considering the size 
of the particles. The use of atomic force 
microscopy (AFM) in the study of 
pharmaceutically related nanoparticles has 
recently been of considerable importance. It is 
possible to acquire very high-resolution 
photographs of particles in their native 
environment using AFM, but at the cost of 
time because it is a form of rastering. Although 
the scale of the particles is below the 
technique's resolution, optical microscopy can 
be very useful. Darkfield methods, for 
instance, allow the presence of nanoparticles 
and hence their number-weighted 
concentration to be observed even though the 
particles themselves are not specifically 
imaged. (27) 
Structure 
Its conduct and stability can be determined 
by the arrangement of components inside the 
nanoparticle. If one is interested in overall 
structural characteristics such as crystal 
structure or degree of amorphous character, a 
variety of traditional techniques such as 
differential scanning calorimetry and powder 
X-ray diffraction are suitable. Relevant 
structural elements, such as layers, may be on 
the molecular scale, considering the limited 
size of nanoparticles. In such cases , higher 
energy dispersion methods such as small-angle 
neutron and X-ray dispersion are needed to 
determine the orientation of molecules. (28) 
Drug release 
Drug release from various formulations 
composed of nanomaterials depends on several 
factors, including pH , temperature, solubility 
of drugs, surface-bound or adsorbed drug 
desorption, nanoparticle matrix drug diffusion, 
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swelling and erosion of the nanoparticle 
matrix, and the combination of erosion and 
diffusion processes. The release of medicine 
can vary depending on the type of nanoparticle 
being used. Various devices such as tablet 
dissolution apparatus and capsule dosage type 
can be tested. (29) 
4. Nanotechnology Applications 
Nanotechnology is a modern approach to 
problem solving that can be used as a set of 
instruments that principle that can be found in 
the pharmaceutical industry. The use of 
nanotechnology instruments in pharmaceutical 
R&D is expected to lead to the industry 
switching from the 'blockbuster drug' paradigm 
to 'personalized medicine'. (30) In the 
pharmaceutical industry, there are convincing 
uses where efficient techniques for 
nanotechnology can be used. (31) 
Targeting cancer cells with nanoparticles 
Cancer remains one of the most challenging 
illnesses nowadays, and brain cancer is one of 
the most challenging malignancies to diagnose 
and cure, largely due to the difficulty in 
bringing imaging and medicinal agents into the 
brain and over the blood-brain barrier. Many 
studies have found that nanoparticles are 
promising to deliver these agents through the 
brain, such as anti-cancer medications, 
doxorubicin, which is attached to polysorbate-
coated nanoparticles, can cross the intact 
blood-brain barrier and be released into the 
brain at therapeutic concentrations. Smart 
superparamagnetic iron oxide particle 
conjugates can be used sooner and more 
reliably than recorded approaches to target and 
locate brain tumors. (32) It is understood that 
the targeting and intracellular diffusion of 
nanoparticles can be further improved by folic 
acid mixed with polyethylene glycol. 
Therefore, nanomaterial has a huge ability to 
kill cancer cells as a drug carrier. (33) 
Nanoparticle-mediated delivery of siRNA 
With a wide number of applications, short 
interfering RNA (siRNA) is emerging as a 
versatile means of regulating gene expression. 
Important improvements in the delivery system 
would include the translation of nucleic acid-
based therapy into clinical trials. To control 
RNAi transmission, Quantum dots (QD) were 
used. For in vitro RNAi transmission, PLGA 
and PLA dependent nanoparticles have also 
been used. Although the delivery of siRNA 
using different nanomaterials has had some 
success, it is difficult to track their 
transmission and control their transfection 
performance without an effective monitoring 
agent or marker. (34) 
Targeting angiogenesis with nanoparticles 
Aggressive tumour growth underlies 
vigorous angiogenesis. Therefore, starving 
tumour cells is one of the pathways used to 
prevent angiogenesis. Via a diverse series of 
mediators, angiogenesis is regulated and recent 
research suggests that integrin alpha-vβ3 and 
vascular endothelial growth factors (VEGFs) 
play significant regulatory roles. Therefore, a 
promising anti-angiogenesis technique for 
treating a wide spectrum of solid tumours is 
the selective activation of alpha-vβ3 integrin 
and VEGFs. One technique is to coat 
nanoparticles with peptides that bind directly 
to the integrin of alpha-vβ3 and the receptor of 
VEGF. It is known that the synthetic peptide 
containing the Arg-Gly-Asp (RGD) sequence 
binds directly to the alpha-vβ3 integrin 
expressed in angiogenic blood vessels on 
endothelial cells, which can potentially inhibit 
tumour growth and proliferation. (35) 
Targeting macrophages to control 
inflammation 
A rational approach to macrophage-specific 
targeting with nanoparticles has been 
established by the ability of macrophages for 
rapid identification and clearing of foreign 
particles. The capacity of macrophages to 
secrete a multitude of inflammatory mediators 
helps them in many diseases to suppress 
inflammation. Thus, in many human and 
animal illnesses, macrophages are important 
therapeutic targets. While most microbes can 
be destroyed by macrophages, certain 
microorganisms (Toxoplasma gondii, 
Leishmania sp, Mycobacterium tuberculosis 
and Listeria monocytogenes) have evolved a 
possible capacity to withstand macrophage 
phagocytosis operation. This pathogens 
subvert the molecular machinery of a 
macrophage engineered to kill them and in 
transformed lysosomes come to live. To 
remove cellular reservoirs, nanoparticles-
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mediated delivery of antimicrobial agent(s) 
into pathogen-containing intracellular vacuoles 
in macrophages may also be useful. 
This method can be used to obtain the 
concentration of medicinal drugs in the 
vacuoles of compromised macrophages and to 
reduce the side effects of drug administration 
and the production of pro-inflammatory 
cytokines. The nanoparticles of polyalkyl-
cyanoacrylates (PACA) have been used as a 
carrier to attack anti-leishman drugs in 
macrophages. (36) 
Treatment of Cardiovascular Diseases 
In human life and wellbeing, cardiovascular 
diseases (CVDs) have been a significant threat. 
While several medications that work by 
various modes of action are present on the 
market as traditional CVD treatment 
formulations, due to poor water solubility , low 
biological effectiveness, non-targeting, and 
drug tolerance, they are still far from 
satisfactory. With the advancement of 
nanotechnology, nano drug delivery systems 
(NDDSs) offer a modern drug delivery 
approach for the treatment of CVDs, 
demonstrating significant advantages in 
solving the above-mentioned problems. (37) 
Glaucoma treatment 
Nanodiamonds that are found in contact 
lenses are connected to medications to combat 
glaucoma. The nanodiamond-released drug 
molecules come in contact with tears, offering 
a more stable dose than frequently happens 
with eye drops. 
Dental implants 
By attaching nanotubes to the implant 
material's surface, researchers are developing 
dental implants. They also shown the potential 
to inject anti-inflammatory drugs into the 
nanotubes, which can be added directly to the 
region surrounding the implant. They have also 
demonstrated that bone adheres more to 
nanotubes of titanium dioxide than to the 
surface of regular titanium implants. (38) 
Diabetes treatment 
Researchers have created nanoparticles 
which, when glucose levels increase, release 
insulin. The nanoparticles include insulin as 
well as an enzyme that dissolves at high 
glucose levels. Insulin is released as the 
enzyme dissolves. These nanoparticles were 
able to regulate blood sugar levels for several 
days during a laboratory examination. 
A sponge-like matrix that contains insulin as 
well as nanocapsules containing an enzyme is 
another strategy being created to release 
insulin. The nanocapsules emit hydrogen ions 
that bind to the fibres that make up the matrix 
as the glucose level increases. The hydrogen 
ions positively charge the fibres, repel each 
other and build openings in the matrix from 
which insulin is emitted. (39) 
Autoimmune diseases treatment 
Nanoparticles are used to transmit antigens 
to the blood stream with a specific condition in 
a process that is being established to treat 
autoimmune diseases. The antigens reset the 
immune system, preventing healthy cells from 
being damaged by white blood cells. This 
procedure was tested with positive results in 
the laboratory on mice with a condition similar 
to multiple sclerosis. (40) 
Prevention to aging 
A system designed to tackle ageing uses 
mesoporous nanoparticles with a coating that, 
when an emzyme contained in ageing cells is 
present, releases the nanoparticle material. 
Face creams that use stem cell-derived proteins 
to avoid face ageing. These proteins are 
encapsulated in nanoparticles of the liposome 
that combine with skin cell membranes to 
allow the proteins to be delivered. 
A nanoparticle that can pass through mucus-
coating surfaces such as lung tissue has been 
developed by researchers. This ability to 
penetrate the mucus layer can include 
preventive medications for the ability to coat 
lung tissue. (41) 
Medical implants 
Medical implants are made of porous plastic 
and coated with carbon nanotubes. For 
example, when a shift in blood chemistry 
signals a problem, medicinal drugs that are 
bound to the nanotubes may be released into 
the bloodstream. These devices, referred to as 
biocapsules, are being designed by NASA to 
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shield astronauts from the effects of radiation, 
but the devices can also be useful for releasing 
insulin to patients with diabetes or for 
administering chemotherapy drugs directly to 
tumors. (42) 
Diagnostics 
Carbon nanoparticles (CNPs) and carbon 
quantum dots (CQDs) provide enticing 
opportunities for the delivery and tracking of 
visual drug effects for medicinal treatment and 
bioimaging diagnostics. (43) 
5. Hazards of Nanotechnology  
In contrast to bulk materials, nanomaterials 
are designed for their special (surface) 
properties. As the surface is the body tissue 
touch layer and a primary determinant of 
particle reaction, these particular properties 
need to be studied from a toxicological point 
of view. It should be predicted that these same 
features would also have an effect on the 
toxicity of certain particles as nanoparticles are 
used for their particular reactive properties. 
Although existing drug and system assessment 
tests and procedures could be sufficient to 
identify certain risks associated with the use of 
these nanoparticles, it cannot be assured that 
all possible risks can be identified by these 
assays. Therefore, it can need additional 
assays. (44) 
The qualitatively distinct physico-chemical 
properties of nanoparticles are related to 
micron-sized particles, which may result in 
changed body distribution, blood brain barrier 
flow, and blood coagulation pathways 
becoming activated. Special focus should be 
put on investigations of (pharmaco)kinetics 
and propagation studies of nanoparticles in 
terms of these characteristics. What is 
currently missing is a clear understanding of 
the biological activity of nanoparticles as 
regards both organ and cellular dissemination 
in vivo. (45) 
6. Conclusion 
A creative approach to problem solving is 
all about nanotechnology which is essentially a 
set of instruments which concepts that have 
possible uses in the pharmaceutical industry. 
There are convincing uses in the 
pharmaceutical industry where affordable 
nanotechnology techniques can be used, 
against the prevalent notion that 
nanotechnology techniques are exotic, too 
advanced, disruptive and not ideal for fast 
commercialization of drugs. Although it is 
clear that many techniques are still at the 
design stage of the nanotechnology toolbox, a 
variety of them can also be extended to the 
method and product production of 
pharmaceuticals. 
In addition to the drug delivery systems in 
cancer have many barriers such as immune 
clearance or hepatic, renal. Thus, to improve 
treatment and overcome these problems the 
nanoparticle-loaded drug is one the solution. 
(46) 
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